Publication: Macrophage activation syndrome: Early diagnosis is key
Issued Date
2018-01-01
Resource Type
ISSN
1179156X
Other identifier(s)
2-s2.0-85059032918
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Open Access Rheumatology: Research and Reviews. Vol.10, (2018), 117-128
Suggested Citation
Butsabong Lerkvaleekul, Soamarat Vilaiyuk Macrophage activation syndrome: Early diagnosis is key. Open Access Rheumatology: Research and Reviews. Vol.10, (2018), 117-128. doi:10.2147/OARRR.S151013 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/47046
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Macrophage activation syndrome: Early diagnosis is key
Author(s)
Other Contributor(s)
Abstract
© 2018 Lerkvaleekul and Vilaiyuk. Macrophage activation syndrome (MAS) is a life-threatening condition, and it is a subset of hemophagocytic lymphohistiocytosis (HLH). The clinical features include a persistent high-grade fever, hepatosplenomegaly, lymphadenopathy, hemorrhagic manifestations, and a sepsis-like condition. From the clinical features, it is usually difficult to differentiate between a true sepsis, disease flare-ups, or MAS. Although the laboratory abnormalities are similar to those of a disseminated intravascular coagulation, which shows pancytopenia, coagulopathy, hypofibrinogenemia, and an elevated d-dimer test, it can also be a late stage of MAS. Currently, MAS is still underrecognized and usually results in delayed in diagnosis, which leads to high morbidity and mortality. This literature review was conducted in the context of the clinical manifestations and the laboratory abnormalities in MAS, which might provide some clues for an early diagnosis. The best ways for an early recognition and a satisfactory diagnosis were based on the relative changes in the overall parameters from the baseline, together with a thorough and continuous physical examination for these kinds of patients. At present, diagnostic criteria have been proposed for HLH, MAS-associated systemic juvenile idiopathic arthritis, and an MAS-associated systemic lupus erythematosus. Therefore, selecting the proper diagnostic criteria for use is essential because not all of the criteria are suitable for every autoimmune disease.